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Introduction
lesions' 241 . Acute myocardial ischaemia without coronary atheromatosis can also originate from Myocardial infarction with angiographically noran extreme imbalance between oxygen demand mal coronary arteries is a rare event and an enigma and supply or an abnormal haemoglobin-oxygen that has received much attention in the literature 1 '" 61 , dissociation' 251 The prevalence of normal or nearly normal coron-Fibrinopeptide A (FPA), cleaved from fibrinoary arteries is high, however, in certain subsets of gen by thrombin 1261 , is a very sensitive marker of patients with myocardial infarction, such as in thrombosis in vivo' 27 ' 281 . Elevated FPA plasma young women using oral contraceptives and smok-leveIs have been reported in patients with acute ing 17 " 91 , in young men during or following severe my ocardial infarction' 2 *-321 , unstable angina'" 1 physical exercise" 0 " 1 or in very young and venous thromboembolism' 341 . Similarly, betapatients 12 -12 -131 . Suggested mechanisms for the thromboglobulin (BTG) plasma levels reflecting 'unproven combination'" 1 of myocardial infarction enhanced platelet activation' 351 have been shown to and normal coronary arteries include: coronary ^ elevated in patients with acute myocardial spasm" 4 " 171 , coronary emboli' 21 , thrombosis with infarction' 36371 and unstable angina' 37 -381 , spontaneous lysis" 8191 , regression of coronary We measured plasma levels of FPA, BTG and atheromatosis' 20 -211 , trauma' 221 , small vessel disease 1231 platelet factor 4 (PF4) in 11 consecutive patients and angiographically unidentifiable coronary ^^ acute myocardial infarction who underwent intravenous thrombolytic therapy with rtPA and Submitced for publication on 
Methods

PATIENTS AND MANAGEMENT
Inclusion and exclusion criteria for thrombolytic therapy were according to the European Cooperative rtPA study 139 ' except for the time lapse from onset of pain (< 4 h) and anticoagulation that excluded our patients. 100 mg rtPA (predominantly single chain material) provided by Boehringer-Ingelheim, Switzerland, was infused intravenously over 3 h. All patients underwent biplane left ventriculography and selective coronary arteriography between 5 and 19 (mean 10 ±4-5) days after thrombolytic therapy.
COAGULATION AND PLATELET TESTS
Blood samples were taken by careful venepuncture before starting the rtPA infusion and 90 min later during rtPA therapy, but before initiating the heparin infusion. They were collected into precooled sample tubes, containing the following anticoagulants (for 9 ml of blood): 1 ml 0-1 02 M citrate, 1 ml cytosin theophyllin adenosin dipyramidol (CTAD) (Boehringer-Mannheim) supplemented with 200 ug D-phenyl-prolylarginine-chloromethylketone (PPACK) as thrombin inhibitor 1401 . The blood samples were carefully mixed, immediately cooled on ice and centrifuged at 4°C/2500g for 30 min within 1 hour of sampling. The plasma was stored at -70 °C. A record was kept of each blood sample in order to identify eventual difficulties in sampling and processing.
FPA was determined in our laboratory using a previously published radioimmunoassay (RIA) 1281 with the following modifications: cross-reacting fibrinogen was eliminated by bentonite absorption before using the fibrinogen-free supernatant for the RIA. Free antigen was separated from bound antigen by use of an immobilized second goatanti-rabbit antibody (Immunobeads, Bio Rad laboratories). Previously measured levels of FPA in 15 normal individuals were 1-9 ±0-8 ngml~" [321 .
BTG and PF4 were determined by specific ELISA, both obtained from Boehringer-Mannheim, F.R.G. Normal values for BTG are 10-40ngml~'. These values are comparable to BTG levels obtained by RIA [41 ' . PF4 plasma levels were measured in order to exclude in vitro platelet activation by venepuncture artefact (normal range: <10ngml~', a BTG/PF4 ratio <3 indicating in vitro platelet activation 1421 .
In addition, blood samples for plasma creatine kinase/MB levels were taken 8, 12, 16, 24 and 48 h after the onset of thrombolytic therapy.
Results
PATIENTS WITH NORMAL CORONARY ARTERIES (GROUP A)
The three cases (numbers 5,9 and 10) with angiographically normal coronary arteries after myocardial infarction are documented separately in Figs 1-3. All blood samples for FPA and BTG measurements were taken without difficulty.
Case 5 (Fig. 1) A young sportsman, 27 years of age and a regular smoker, had a 4-month history of transient precordial discomfort at rest, but a normal maximal treadmill test, suggesting the possibility of spastic angina. He was admitted with severe nitroglycerin-resistant chest pain that had begun during an ice-hockey match. The electrocardiogram showed an acute inferolateral myocardial infarction. Intravenous thrombolytic therapy with rtPA was initiated 3 h 15 min after the onset of chest pain. A bradycardiac nodal rhythm followed by self-limited ventricular tachycardia/flutter and a sudden relief of chest pain suggested reperfusion 1 h later. Another short episode of ventricular tachycardia 2 h after the end of thrombolytic therapy and a double peaked curve of creatine kinase/MB plasma levels suggested a reocclusion and secondary reperfusion. No further complication occurred. An inferior Q-wave infarction evolved subsequently. However, no regional wall motion abnormality indicative of transmural myocardial infarction was noted angiographically 5 days after the acute event. The coronary arteries were normal, except for systolic narrowing of the left anterior descending artery by myocardial bridging. This abnormality, however, could not be responsible for the acute ischaemic event in the inferior myocardial region, nor probably for the history of transient precordial discomfort at rest, since the diastolic diameter of the left anterior descending artery was also normal. FPA plasma levels were elevated (6-3 ngml~' and 39-4 ng ml" 1 ), indicating thrombosis before and 90 min after initiation of thrombolytic therapy. The corresponding high BTG plasma levels (172 and 256ngml~') and normal PF4 levels (10 and 29 ng ml" 1 ) documented markedly enhanced platelet activation in vitro without activation. Case 9 (Fig. 2) A 43-year-old man, a heavy smoker without history of angina, was admitted with severe nitroglycerin-resistant chest pain and electrocardiographic signs of an acute anterior myocardial infarction. Intravenous thrombolytic therapy with rtPA was initiated 3 h 30 min after onset of pain. Ventricular extrasystoles in salvos 50 min later were interpreted as a reperfusion arrhythmia, since chest pain abruptly disappeared. No complication occurred. Peaking in creatine kinase/MB plasma levels was early. An anterior Q-wave infarction, with loss of R-potentials from VI to V4, developed. Angiography, 19 days after the acute event, showed a localized but distinct apical akinesia, attributable to a long left anterior descending artery. Coronary arteries, however, were normal. FPA plasma levels were elevated (15-3 and 56-4 ng ml" 1 ) before and during thrombolytic therapy, as were BTG plasma levels (284 and 304 ng ml"' respectively), indicating thrombosis and platelet activation. Since PF4 levels (199 and 215 ngml" 1 ) were also elevated, however, additional platelet activation in vitro had to be presumed in this case.
Case 10 (Fig. 3) A 38-year-old man with no history of angina was admitted with nitroglycerin-resistant chest pain that had begun during a soccer game. With typical electrocardiographic signs of acute inferoposterior myocardial infarction, intravenous thrombolytic therapy with rtPA was started 3 h 25 min after the onset of chest pain. The pain diminished gradually during therapy. No reperfusion arrhythmia was noted. Creatine-kinase MB plasma levels peaked very early. An inferior Q-wave infarction evolved within 24 h. No complication occurred. Angiography 10 days later confirmed an inferior akinesia corresponding to the posterior descending branch of a dominant circumflex artery. However, except for minor wall irregularities, the coronary arteries were normal. FPA (73-4 and 119-2ngml-') and BTG (172 and 256 ngml" 1 ) plasma levels were markedly elevated, documenting fibrin formation and platelet activation in vivo with some platelet activation in vitro (PF4 levels 111 and 153ngmr').
patients with normal coronary arteries in Table 1 . The mean age was higher (50-5 ± 10 vs 36 ± 8 years). All patients were admitted with typical clinical and electrocardiographic signs of acute myocardial infarction (five inferoposterior, three anterolateral). Intravenous thrombolytic therapy with rtPA was initiated between 2 and 4h (mean 3-1+0-8h vs 3-4 ±0-1 h in group A) after the onset of chest pain, which disappeared in all but one case, while arrhythmias suggesting reperfusion were noted in 4 out of 8 cases. Peaking of creatine kinase plasma levels occurred within 12 h in 7 out of 8 patients. Q-wave infarction developed in all patients. Angiography 9-7 + 3-7 days after the acute event revealed a normal left ventricle in two cases treated very early, only small hypokinetic zones in two cases, and akinetic or dyskinetic regions corresponding with the electrocardiographic infarct site in four cases. The infarct-related artery was patent in all patients, with a mean residual stenosis of 84+15%. FPA (mean 66-8 ±65-7 ng ml"') and BTG (mean 181 ±75 ng ml" 1 ) plasma levels were elevated before and during thrombolytic therapy in all patients but one (case 11) whose first FPA value was low because of spurious heparin. Three out of 16 FPA values were not taken into account because of sampling difficulties. In 5 out of 13 blood samples a BTG/PF4 ratio <3 indicated some platelet activation in vitro' 421 .
Discussion
PREVALENCE OF NORMAL ANGIOGRAPHY AFTER
MYOCARDIAL INFARCTION
The prevalence of angiographically normal coronary arteries after myocardial infarction is 1-4% according to bigger series' 13 ' 431 . No significant coronary stenosis or zero vessel disease is found in 7-19% of postinfarction patients' 4 ' I3 -2C) . Very young patients' 13 ', however, especially women taking oral contraceptives and smoking* 7 "" 9 ' 19 ' and young men who sustain myocardial infarction during or immediately following severe physical exercise" 01 " have high prevalence (30-45%) of angiographically normal or insignificantly diseased coronary arteries.
PATIENTS WITH SIGNIFICANT CORONARY ARTERY
DISEASE (GROUP B)
The pertinent data and results of patients with significant coronary artery disease after a first myocardial infarction are compared with those of CORONARY SPASM Spasm is the mechanism most often postulated to explain the combination of myocardial infarction and angiographically normal coronary arteries' 14 " 17 ' 431 , although the reported evidence for its role is circumstantial rather than causal. Among 679 young survivors of myocardial infarction undergoing angiography, Gohlke et a/.' 131 found 25 patients with normal coronary arteries, 32 with non-significant (< 50%) lesions and 112 withunifocal disease; none of these patients had a history of repeated angina at rest of the Prinzmetal type prior to myocardial infarction. Oliva et al. demonstrated coronary spasm angiographically in six patients early after acute myocardial infarction 1 ' 4 ', but the spasm consistently occurred at the site of a severe coronary lesion, whereas no spasm was demonstrated in two cases of myocardial infarction and normal coronary arteries' 3 '. Vasospasm has been incriminated in myocardial infarction during or immediately following vigorous excercise 110 '.
The success of early thrombolytic therapy has established the great importance of thrombosis compared with spasm in myocardial infarction. Rentrop et al. demonstrated the negligible effect of intracoronary nitroglycerin very early after the onset of chest pain' 44 '. Vasoconstriction, however, might play a role in reocclusion during thrombolytic therapy 1451 .
Markers of platelet activation do not specifically indicate vasospasm, since aggregating platelets may exert their effect by mechanical obstruction, enhancement of thrombosis or thromboxane A2mediated vasoconstriction. Our measured BTG levels document platelet activation in patients with acute MI whether significant coronary artery disease is present or not. Compared with plasma levels measured between 6 and 32 h after the onset of infarction (64 ±21 ngmr" 321 ), the levels of BTG measured between 2 and 4 h after onset of chest pain were substantially higher. This might reflect a higher platelet activity in the early hours of myocardial infarction. Patients with normal coronary arteries had higher BTG levels than patients with significant coronary disease (257 ±45 vs 181 ±75 ng ml"'). Whether this corresponds to more spastic activity in agreement with Ogasawara et a/.' 4 * 1 remains speculative in view of the small group size in our study.
CORONARY THROMBOSIS
The causal role of thrombosis in acute myocardial infarction and unstable angina with underlying significant coronary artery disease is hardly contested today. In vivo evidence is based on angiography 147 ' 481 , angioscopy 149 ', elevated plasma levels of fibrinopeptide A' 29 " 33 ' and cross-linked fibrin degradation products' 50 -51 ', and the success of early thrombolytic therapy.
To our knowledge, evidence of a direct connection between angiographically normal coronary arteries and in vivo markers of thrombosis has not been provided so far. Elevated plasma levels of fibrinopeptide A measured as early as 3-2 ±0-7 h after the onset of chest pain in patients with enzymatically and electrocardiographically evolving myocardial infarction suggest a causal role of thrombosis. Since FPA levels in patients with normal coronary arteries after thrombolytic therapy are not different from levels in patients with significant residual coronary disease, it might be assumed that thrombosis was the mechanism of coronary occlusion in both groups. The success of thrombolytic therapy and the failure of previously given nitroglycerin in all patients support this assumption.
On the other hand, one cannot exclude the possibility that myocardial ischaemia or necrosis per se, by mechanisms so far not elucidated, such as endothelial damage in the ischaemic territory, may be responsible for the activation of both coagulation and platelets' 381 . A small intracoronary thrombus may not be the sole explanation for the high FPA plasma levels measured. Ischaemia would then be not only the consequence but also a possible cause of further fibrin formation. Elevated FPA levels in unstable angina' 33 ' 38 ' in contrast to stable angina' 37 -38 ' may either favour the hypothesis that intracoronary thrombosis also plays a major role in transient ischaemic episodes at rest, commonly interpreted as coronary spasm, or indicate that severe ischaemia per se activates coagulation and platelets.
Plasma levels of FPA measured between 2 and 4 h after the onset of chest pain were significantly higher than our previously published levels' 30 -32 ', which were measured between 6 and 32 h after the onset of infarction in non-heparinized patients. This might reflect a time-dependent decrease of thrombotic activity in acute myocardial infarction.
Absence of angiographically detectable coronary lesions does not imply a 'normal' coronary artery. Early endothelial cell damage without visible obstruction might have important sequelae, which have been called 'rapid progression of coronary artery disease' 16 '. Platelet deposition on such an endothelial lesion, leading to intense coronary spasm of sufficient duration to provoke stasis and finally, thrombosis, is a sequence of events postulated to explain myocardial infarction with angicgraphically normal coronary arteries' 6 ' 52 ' 531 . A reduced activity and enhanced inhibition of endogenous tissue plasminogen activator in patients with myocardial infarction without visible coronary artery disease 154 ' might, however, lead to thrombosis without preceding spasm.
Finally, FPA is not a specific marker of coronary thrombosis, but could also reflect left ventricular, venous or extravascular fibrin generation. However, none of our three young patients with normal coronary arteries had a left ventricular aneurysm, atrial enlargement or fibrillation, signs of venous stasis or a central catheter. The venepuncture was done with extreme caution and blood samples obtained without difficulty. Extracoronary fibrin formation therefore seems improbable.
Conclusion
Myocardial infarction occurs in spite of angiographically normal coronary arteries. Fibrin formation and platelet activation are of crucial importance whether a significantly diseased or an apparently normal coronary artery occludes, as shown by equally elevated plasma levels of fibrinopeptide A very early after the onset of chest pain, the ineffectiveness of nitroglycerin and the efficacy of thrombolytic therapy.
While coronary spasm alone has not been shown conclusively to be responsible for myocardial infarction, an adjunctive role cannot be excluded. High beta-thromboglobulin plasma levels indicate a marked enhancement of platelet activity in the early hours of myocardial infarction, whether significant coronary disease is present or not.
